News & Videos - OXURION - English

Leuven, BELGIUM – January 20, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on January 16, 2025, from Atlas Special Opportunities, LLC indicating that as of January 13, 2025, it held 812,202 shares of the then outstanding 3,638,344 shares, and therefore...

Leuven, BELGIUM – January 14, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received an amended transparency notification as follows: Oxurion received a transparency notification on January 13, 2025, from Atlas Special Opportunities, LLC indicating that as of December 30, 2024, it held 35,039 shares of the then outstanding 3,192,223 shares, and...

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment [1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM – 13 January, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May...

Leuven, BELGIUM – January 13, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on January 13, 2025, from Atlas Special Opportunities, LLC indicating that as of January 9, 2025, it held 428,150 shares of the then outstanding 3,192,223 shares, and therefore...

Leuven, BELGIUM – January 6, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on January 6, 2025, from Atlas Special Opportunities, LLC indicating that as of January 1, 2025, it held 624,817 shares of the then outstanding 3,192,223 shares, and therefore crossed...

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment [1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM – 3 January, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May...

Leuven, BELGIUM – January 3, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on December 30, 2024, from Atlas Special Opportunities, LLC indicating that as of December 30, 2024, it held 35,039 shares of the then outstanding 2,567,406 shares, and therefore...

LEUVEN, BELGIUM –31 December 2024 – 6:00PM , Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces a short postponement of approximately four weeks for the signing of its contemplated strategic transaction. The delay is due to ongoing discussions between the parties, prompted by the better than expected financial results of the target. The contemplated transaction, which represents a significant step in Oxurion's strategic realignment, remains a...

LEUVEN, BELGIUM – 19 December 2024 – 6:00PM , Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces that the French Ministry of the Economy, Finance and Industry has approved the Company's contemplated strategic transaction. The contemplated transaction, which is a significant step in Oxurion's strategic realignment, has been approved by the French regulatory authorities under specific conditions aimed at protecting the interests of the French...

Leuven, BELGIUM – December 12, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on December 11, 2024, from Atlas Special Opportunities, LLC indicating that as of December 11, 2024, it held 331,543 shares of the then outstanding 2,567,406 shares, and therefore...

Leuven, BELGIUM – December 9, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received transparency notifications as follows: Oxurion received a transparency notification on December 6, 2024, from Atlas Special Opportunities, LLC indicating that as of December 5, 2024, it held 564,856 shares of the then outstanding 2,567,406 shares, and therefore...

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment [1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM – 5 December, 2024 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May...

Leuven, BELGIUM – December 4, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on December 3, 2024, from Atlas Special Opportunities, LLC indicating that as of December 3, 2024, it held 97,098 shares of the then outstanding 2,002,550 shares, and therefore...

Leuven, BELGIUM – December 2, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on November 27, 2024, from Atlas Special Opportunities, LLC indicating that as of November 27, 2024, it held 175,690 shares of the then outstanding 2,002,550 shares, and therefore...

Oxurion announces that its potential acquisition is subject to foreign investment control LEUVEN, BELGIUM - November 28, 2024 - 7:00 pm , Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces that the French Ministry of the Economy, Finance and Industry is currently examining a request for prior authorisation under Foreign Direct Investment (FDI) control. Oxurion's acquisition falls within the scope of Articles L. 151-3 and R. 151-1 et seq. of the...

Leuven, BELGIUM – November 14, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on November 14, 2024, from Atlas Special Opportunities, LLC indicating that as of November 12, 2024, it held 267,064 shares of the then outstanding 2,002,550 shares, and therefore...

Leuven, Belgium – November 5, 2024 – 10:30 AM CET – Oxurion NV (Euronext Brussels: OXUR) announces that it terminated the private judicial reorganization (PRJ) procedure initiated on August 22, 2024. The Company had not taken any step towards its creditors within such procedure as it continued to dialogue with its creditors outside the framework of that procedure. Following such discussions, amicable agreements were reached with its key creditors. These creditors were mainly suppliers...

Oxurion NV: Belangrijkste ontwikkelingen en lijn met betrekking tot de lopende potentiële overname LEUVEN, BELGIË - 29 oktober 2024 – 22u00 CET , Oxurion NV (Euronext Brussels: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt aan dat zij de due diligence-fase heeft afgerond met betrekking tot de overname van een meerderheidsbelang van 80% in een CRO (Contract Research Organisation), na de ondertekening van een intentieverklaring ( zie persbericht van 8 juli 2024 ). De...

Leuven, BELGIUM – October 24, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on October 24, 2024, from Atlas Special Opportunities, LLC indicating that as of October 23, 2024, it held 383,105 shares of the then outstanding 2,002,550 shares, and therefore...

Leuven, BELGIUM – October 14, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notifications as follows: Oxurion received a transparency notification on October 11, 2024, from Atlas Special Opportunities, LLC indicating that as of October 8, 2024, it held 500,204 shares of the then outstanding 2,002,550 shares, and therefore...